Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer

Gogineni, Emile; Rana, Zaker; Soberman, Danielle; Sidiqi, Baho; D'Andrea, Vincent; Lee, Lucille; Potters, Louis; Parashar, Bhupesh

doi:10.1016/j.ijrobp.2020.11.003

Cited by 11 publications

(10 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of patients received hormone therapy, none were treated by surgery and all patients were treated with LDR brachytherapy. Therapy-related side effects were mild, most probably due to the applied RT protocol and in agreement with previous reports on LDR brachytherapy-induced late toxicities in prostate cancer patients [37][38][39][40]. Patient selection criteria allowed for the regular follow-up of the patients up to 36 months after the initiation of radiotherapy in order to investigate long-term phenotypical changes in several lymphocyte subpopulations known to be important players in the anti-tumor innate and adaptive immune response.…”

Section: Discussionsupporting

confidence: 85%

Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations

Balázs

Kocsis

Ágoston

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: The development of cancer and anti-tumor therapies can lead to systemic immune alterations but little is known about how long immune dysfunction persists in cancer survivors. Methods: We followed changes in the cellular immune parameters of prostate cancer patients with good prognostic criteria treated with low dose rate brachytherapy before and up to 3 years after the initiation of therapy. Results: Patients before therapy had a reduced CD4+ T cell pool and increased regulatory T cell fraction and these alterations persisted or got amplified during the 36-month follow-up. A significant decrease in the total NK cell number and a redistribution of the circulating NK cells in favor of a less functional anergic subpopulation was seen in patients before therapy but tumor regression led to the regeneration of the NK cell pool and functional integrity. The fraction of lymphoid DCs was increased in patients both before therapy and throughout the whole follow-up. Increased PDGF-AA, BB, CCL5 and CXCL5 levels were measured in patients before treatment but protein levels rapidly normalized. Conclusions: while NK cell dysfunction recovered, long-term, residual alterations persisted in the adaptive and partly in the innate immune system.

show abstract

Section: Discussionsupporting

confidence: 85%

Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations

Balázs

Kocsis

Ágoston

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…There are variables that can also influence the toxicity outcome. In the first place, several studies have identified much higher toxicity levels in combined radiotherapeutic treatments, as evaluated in our research, compared to monotherapy [ 37 , 38 ]. Also, another study that used the IPSS (International Prostate Symptom Score) found that the main toxicities were greater incontinence, hematuria, and clinically important dysuria [ 39 ].…”

Section: Discussionmentioning

confidence: 92%

Biochemical failure and toxicity in treatment with brachytherapy and external beam radiotherapy compared with radical prostatectomy in localized prostate cancer

Galdos-Bejar

Belanovic-Ramirez

Alvarado

et al. 2022

Rep Pract Oncol Radiother.

View full text Add to dashboard Cite

show abstract

“…There are no prospective studies comparing brachytherapy with SBRT. However, the results of retrospective studies in terms of biochemical control and toxicity do not show differences between the two treatment techniques, which would have to be confirmed by randomized studies [30,31].…”

Section: Sbrt Vs Brachytherapymentioning

confidence: 93%

Extreme Hypofractionation with SBRT in Localized Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

Prostate cancer is the most commonly diagnosed cancer among men around the world. Radiotherapy is a standard of care treatment option for men with localized prostate cancer. Over the years, radiation delivery modalities have contributed to increased precision of treatment, employing radiobiological insights to shorten the overall treatment time, improving the control of the disease without increasing toxicities. Stereotactic body radiation therapy (SBRT) represents an extreme form of hypofractionated radiotherapy in which treatment is usually delivered in 1–5 fractions. This review assesses the main efficacy and toxicity data of SBRT in non-metastatic prostate cancer and discusses the potential to implement this scheme in routine clinical practice.

show abstract

Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer

Cited by 11 publications

References 51 publications

Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations

Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations

Biochemical failure and toxicity in treatment with brachytherapy and external beam radiotherapy compared with radical prostatectomy in localized prostate cancer

Extreme Hypofractionation with SBRT in Localized Prostate Cancer

Contact Info

Product

Resources

About